company background image
PHGE logo

BiomX NYSEAM:PHGE Stock Report

Last Price

US$0.64

Market Cap

US$9.9m

7D

12.2%

1Y

-77.9%

Updated

26 Dec, 2024

Data

Company Financials +

BiomX Inc.

NYSEAM:PHGE Stock Report

Market Cap: US$9.9m

PHGE Stock Overview

A clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. More details

PHGE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 1.4% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 24.5% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

+ 3 more risks

My Notes

Capture your thoughts, links and company narrative

BiomX Inc. Competitors

Apollomics

NasdaqCM:APLM

US$12.4m

Ensysce Biosciences

NasdaqCM:ENSC

US$13.0m

Turnstone Biologics

NasdaqGM:TSBX

US$10.5m

BioRestorative Therapies

NasdaqCM:BRTX

US$10.7m

Price History & Performance

Summary of share price highs, lows and changes for BiomX
Historical stock prices
Current Share PriceUS$0.64
52 Week HighUS$8.55
52 Week LowUS$0.48
Beta1.29
1 Month Change16.33%
3 Month Change-39.44%
1 Year Change-77.93%
3 Year Change-95.98%
5 Year Change-99.34%
Change since IPO-99.34%

Recent News & Updates

Recent updates

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

Jan 29
What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

Shareholder Returns

PHGEUS BiotechsUS Market
7D12.2%2.1%2.8%
1Y-77.9%-3.8%24.5%

Return vs Industry: PHGE underperformed the US Biotechs industry which returned -3.8% over the past year.

Return vs Market: PHGE underperformed the US Market which returned 24.5% over the past year.

Price Volatility

Is PHGE's price volatile compared to industry and market?
PHGE volatility
PHGE Average Weekly Movement13.8%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: PHGE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PHGE's weekly volatility has decreased from 32% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201565Jonathan Solomonwww.biomx.com

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.

BiomX Inc. Fundamentals Summary

How do BiomX's earnings and revenue compare to its market cap?
PHGE fundamental statistics
Market capUS$9.88m
Earnings (TTM)-US$8.70m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Is PHGE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHGE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.71m
Earnings-US$8.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHGE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:41
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BiomX Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd